All In Biotech

NDA 208151 · Alcon Labs INC

Isopto Atropine

Atropine Sulfate · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Aug 12, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Dec 1, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

414

74 Phase 3, 30 recruiting

FAERS reports

2,595

2,182 serious, 414 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 13, 2026.

Atropine Sulfate Ophthalmic Solution, 1% is indicated for: Atropine Sulfate Ophthalmic Solution, 1% is a muscarinic antagonist indicated for: Mydriasis ( 1.1 ) Cycloplegia ( 1.2 ) Penalization of the healthy eye in the treatment of amblyopia ( 1.3 ) 1.1 Mydriasis 1.2 Cycloplegia 1.3 Penalization of the healthy eye in the treatment of amblyopia

Mechanism: Atropine acts as a competitive antagonist of the parasympathetic (and sympathetic) acetylcholine muscarinic receptors. Topical atropine on the eye induces mydriasis by inhibiting contraction of the circular pupillary sphincter muscle normally stimulated by acetylcholine. This inhibition allows the countering radial pupillary dilator muscle to contract which results in dilation of the pupil. Additionally, atropine induces cycloplegia by paralysis of the ciliary muscle which controls accommodation while viewing objects.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 1, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • ISOPTO ATROPINE · ATROPINE SULFATE 1% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT2

Clinical trials

Interventional ClinicalTrials.gov studies with "Atropine" as an intervention, any sponsor and status, largest first.

All 414 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective315
  • off label use214
  • macular degeneration199
  • nausea192
  • pyrexia162
  • diarrhoea150
  • pain138
  • malaise132
  • headache129
  • death124
  • weight decreased120
  • constipation117

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200455
200562
200650
200755
200873
200945
201075
201167
201271
201360
201468
201578
2016117
201797
2018125
2019184
2020164
2021152
2022230
2023237
2024236
2025189
2026104

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,885 on PubMed

Sponsor: Alcon Labs INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.